|
|
Other links at Articles > Hematology-Oncology |
| 4. |
TKIs in Lung Cancer: Why Save the Best for Last?
|
|
|
Dr. Mark Kris cites ample evidence for use of erlotinb or gefitinib as first-line therapy in patients with NSCLC but finds TKIs offer less benefit as second-line therapy. Medscape Hematology-Oncology
|
|
|